Buy & Sell Koninklijke Philips NV (PHG) – Koninklijke Philips NV Price Today
Aura AI Summary
Key Stats
- $24.42BMarket Cap
- HealthSector
- -20.51%3M Drawdown
- $30.88BEnterprise Value
- 3.95%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 76 daysTypical Hold Time
Koninklijke Philips NV (PHG) is currently valued at a market capitalization of $24.42B, with an enterprise value of $30.88B. Over the past 52 weeks, Koninklijke Philips NV has traded between a low of $22.06 and a high of $32.91, highlighting its annual price range. Over the past three months, Koninklijke Philips NV has recorded a drawdown of -20.51%, reflecting recent price volatility. Koninklijke Philips NV offers a dividend yield of 3.95%, with the most recent dividend of $1.01 paid on 13 May 26. On average, investors hold Koninklijke Philips NV for approximately 76 days, indicating typical investor behavior on the platform.
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Most Recent News
IBM shifts to recurring software revenue and hybrid cloud, boosting its long-term investment appeal.
IBM has evolved into a more predictable and higher-quality business by focusing on recurring software revenue and enterprise integration. The acquisition of Red Hat strengthens its position in hybrid cloud, maintaining IBM's relevance in enterprise I...
Novo Nordisk shares jump 25% on new oral Ozempic and Wegovy launches and FDA approvals
Novo Nordisk's stock surged 25% in the past month, recovering from multi-year lows due to the launch of oral versions of its Ozempic and Wegovy weight loss drugs, FDA approvals, and telehealth partnerships. The company also slightly raised its sales ...
U.S. SEC settles fraud claims with Gautam and Sagar Adani, penalties paid, criminal charges likely dropped
The U.S. Securities and Exchange Commission (SEC) has reached a settlement with Indian billionaire Gautam Adani and his nephew Sagar Adani over civil fraud allegations related to misleading investors in solar energy contracts. Gautam Adani will pay a...
